HeartSciences (HSCS) Receivables - Net (2022 - 2025)
HeartSciences (HSCS) reported Receivables - Net of $4350.0 for Q2 2025, down 70.41% quarter-over-quarter from $14700.0 in Q1 2024.
HeartSciences (HSCS) Receivables - Net (2022 - 2025) Analysis & Trends
HeartSciences has reported Receivables - Net for 4 years, with the latest figure at $4350.0 in Q2 2025.
- For the quarter ending Q2 2025, Receivables - Net changed N/A year-over-year to $4350.0; the trailing twelve-month figure through Apr 2025 stood at $4350.0 (changed N/A YoY), and the FY2025 full-year result was $4350.0, changed N/A from the prior year.
- Receivables - Net for Q2 2025 stood at $4350.0, down from $14700.0 in the prior quarter.
- The five-year high for Receivables - Net was $14700.0 in Q1 2024, with the low at $2321.0 in Q2 2022.
- Historically, Receivables - Net has averaged $6317.8 across 4 years, with a median of $4125.0 in 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn |
| 10 | HeartSciences | 3.66 Mn | 261,591.68 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | 4,350.00 |
| Apr 30, 2025 | 4,350.00 |
| Jan 31, 2024 | 14,700.00 |
| Jan 31, 2024 | 14,700.00 |
| Oct 31, 2023 | 3,900.00 |
| Oct 31, 2023 | 3,900.00 |
| Apr 30, 2022 | 2,321.00 |
| Apr 30, 2022 | 2,321.00 |